Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Meditation and Yogic Breathing-driven Modulation of Neurofluid Coupling and Brain Clearance (SPANDHA)

5 november 2026 bijgewerkt door: Balachundhar Subramaniam, Beth Israel Deaconess Medical Center

This study will examine whether meditation and yogic breathing can alter brain fluid movement and waste clearance in healthy adults. It will also evaluate the GLYMPHOMETER, a new external forehead-worn device designed to objectively measure changes in brain fluid movement and exchange during meditation.

Studie Overzicht

Toestand

Nog niet aan het werven

Conditie

Gedetailleerde beschrijving

The glymphatic system is a brain waste-clearance pathway that facilitates the movement of cerebrospinal fluid (CSF) and interstitial fluid and is thought to play an important role in maintaining brain homeostasis. Emerging evidence suggests that respiration, autonomic activity, and changes in cerebral blood flow may influence CSF dynamics and related neurofluid processes. However, the effects of voluntary breathing practices and meditation on these physiological mechanisms in humans remain incompletely understood.

The SPANDHA study will investigate whether structured yogic breathing (Pranayama; specifically Nadi Shuddhi) and/or meditation (Shoonya meditation) are associated with changes in neurofluid dynamics and related physiological measures. The study will use the GLYMPHOMETER, a forehead-mounted multimodal device designed to measure physiological signals associated with neurofluid coupling during naturalistic meditation and breathing practices. The system incorporates multi-wavelength electroencephalography (EEG) and near-infrared spectroscopy (NIRS) to characterize changes in cerebral electrical activity, cerebral hemodynamics, and neurofluid-related dynamics while participants engage in the interventions.

The study will enroll approximately 100 participants, including 50 novice and 50 experienced practitioners. Using a 2-sequence crossover, participants will complete two study visits involving meditation and yogic breathing conditions. The study will evaluate changes in measures of neurofluid dynamics, cerebral compliance, autonomic regulation including heart-rate variability (HRV), and EEG-derived brain states associated with the interventions. Participants will be stratified by experience level (novice/advance) and randomized within each stratum to one of the two intervention sequences.

A subset of participants will undergo additional validation assessments using phase-contrast magnetic resonance imaging (MRI) and blood-based biomarkers. These assessments will be used to examine the relationship between measurements obtained with the GLYMPHOMETER and established measures of CSF and cerebrovascular physiology.

The primary objective of the study is to characterize the acute physiological effects of meditation and yogic breathing on neurofluid dynamics and related brain and autonomic measures. The findings may provide preliminary evidence regarding the feasibility of using voluntary breathing and meditation practices to modulate physiological processes associated with glymphatic function and may inform future studies of non-pharmacological approaches to brain health.

Studietype

Ingrijpend

Inschrijving (Geschat)

120

Fase

  • Niet toepasbaar

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

Studie Locaties

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

25 jaar tot 60 jaar (Volwassen)

Accepteert gezonde vrijwilligers

Ja

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Inclusion Criteria:

  • Healthy adults, 25-60 years old.
  • Novice or Advanced as defined above.
  • Fluent in English.
  • Able to travel to BIDMC site for two days approximately 3-7 days apart.

Exclusion Criteria:

  • History of neurological and/or neurodegenerative disorders (e.g., epilepsy, stroke, mild cognitive impairment, dementia)
  • History of cardiovascular and respiratory illnesses
  • History of major psychiatric disorders (e.g., schizophrenia, bipolar disorder)
  • Currently diagnosed mental health issues (e.g., anxiety, depression)
  • Current use of psychoactive medications, including medications prescribed for anxiety, depression, or other psychiatric conditions, or current use of stimulants or other medications that may substantially affect central nervous system function or study outcomes.
  • Skin ailments, abrasions or contusions, particularly located on the forehead and face

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Ander
  • Toewijzing: Niet-gerandomiseerd
  • Interventioneel model: Crossover-opdracht
  • Masker: Geen (open label)

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Actieve vergelijker: Novice Meditators

Less than 1 year of consistent meditation practice.

Nadi Shuddhi is a structured yogic breathing practice involving slow, alternating respiration through the left and right nostrils in a prescribed sequence.

Shoonya meditation is a structured contemplative practice characterized by conscious non-doing, in which participants maintain a relaxed, alert state while minimizing deliberate attentional selection, cognitive elaboration, and engagement with internal or external stimuli.

Actieve vergelijker: Advanced Meditators

More than 5 years or a minimum of 2500 hours of consistent meditation practice

Nadi Shuddhi is a structured yogic breathing practice involving slow, alternating respiration through the left and right nostrils in a prescribed sequence.

Shoonya meditation is a structured contemplative practice characterized by conscious non-doing, in which participants maintain a relaxed, alert state while minimizing deliberate attentional selection, cognitive elaboration, and engagement with internal or external stimuli.

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Acquisition of physiological data using the GLYMPHOMETER during meditation and yogic breathing sessions.
Tijdsspanne: At each study visit while the meditation is being practiced. Expected acquisition window: 20 minutes; Total number of visits: 2

Participants meeting threshold for analyzable device recordings.

At each study visit while the meditation is being practiced. Expected acquisition window: 20 minutes; Total number of visits: 2

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Neurofluid-related physiological measures during Shoonya meditation and Nadi Shuddhi breathing.
Tijdsspanne: At each study visit while the meditation is being practiced. Expected acquisition window: 20 minutes; Total number of visits: 2

Changes in GLYMPHOMETER-derived measures of neurofluid coupling, during Shoonya meditation and Nadi Shuddhi breathing.

(Measurement device: Glymphometer; Measure: Neurofluid coupling aka Fluid dynamics in brain)

At each study visit while the meditation is being practiced. Expected acquisition window: 20 minutes; Total number of visits: 2
Autonomic regulation during Shoonya meditation and Nadi Shuddhi breathing.
Tijdsspanne: At each study visit while the meditation is being practiced. Expected acquisition window: 20 minutes; Total number of visits: 2

Changes in heart-rate variability (HRV) during Shoonya meditation and Nadi Shuddhi breathing.

At each study visit while the meditation is being practiced. Expected acquisition window: 20 minutes; Total number of visits: 2
Very-low-frequency physiological signal characteristics
Tijdsspanne: At each study visit while the meditation is being practiced. Expected acquisition window: 20 minutes; Total number of visits: 2

Changes in predefined very-low-frequency (0.001-0.1 Hz) signal characteristics derived from GLYMPHOMETER medical™ recordings and their relationship to neurofluid-related measures.

At each study visit while the meditation is being practiced. Expected acquisition window: 20 minutes; Total number of visits: 2

Andere uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Differences in neurophysiological responses according to meditation experience.
Tijdsspanne: From date of enrollment until end of both study visits; assessed up to 4 weeks from enrollment.

Comparison of changes in GLYMPHOMETER-derived measures of neurofluid coupling between novice and advanced meditators.

From date of enrollment until end of both study visits; assessed up to 4 weeks from enrollment.
Mindful Attention Awareness Scale
Tijdsspanne: Once at Baseline. Estimated acquisition window: 5-8 minutes

We assess for change in Mindfulness levels by using a validated scale for this purpose namely, Mindfulness Attention Awareness Scale (MAAS). The scale measures the individuals' ability for receptive awareness and attention to present. This aids in evaluating any change on the individual's awareness levels after the Inner engineering intervention. We compute the MAAS scores for each participant which is a mean score for 15 item questionnaires and compare the pre & post intervention results to look for change. Participants are asked to rate on a scale of 1 (Almost Always) to 6 (Almost Never) to assess the frequency of occurrence of each experience. Mean is then computed using items from each of the 15 questions to create a MAAS score, ranging from 0 to 6. Higher MAAS scores indicate better mindfulness state.

Once at Baseline. Estimated acquisition window: 5-8 minutes
Meditation Depth Questionnaires
Tijdsspanne: At each study visit after the meditation practice is completed. Expected acquisition window: 10-15 minutes; Total number of visits: 2

This 30-item measure assesses the subjective depth of meditation across progressively deeper experiential states. Items are typically rated on a 5-point Likert scale and are grouped into five empirically derived domains: hindrances, relaxation, personal-self/concentration, essential/transpersonal qualities, and transpersonal-self/non-duality. Together, these domains capture experiences ranging from obstacles and relaxation during meditation to focused concentration, transpersonal qualities, and experiences of diminished self-boundaries or non-dual awareness.

At each study visit after the meditation practice is completed. Expected acquisition window: 10-15 minutes; Total number of visits: 2
Correlation between GLYMPHOMETER-derived neurofluid metrics and MRI-based neurofluid dynamics (Validation of Portable Device).
Tijdsspanne: From date of enrollment until end of both study visits; assessed up to 4 weeks from enrollment.

This outcome evaluates the concurrent validity of the portable device against the gold standard. The statistical method will be a correlation analysis (Pearson or Spearman, as appropriate based on data distribution).

  • Measurement 1 (Variable A): Neurofluid coupling oscillations measured via the GLYMPHOMETER medical™ device (measured as relative changes in HbO, HbR, HbT, and CSF/H2O proportional signal including interhemispheric correlation coefficient across these neurofluid compartments while gating each of them to very low frequency, respiratory and cardiac frequency bands).
  • Measurement 2 (Variable B): Global neurofluid dynamics and CSF flow measured via 3T MRI using fast fMRI and phase-contrast sequences (measured as BOLD-CSF coupling magnitude and CSF stroke volume in mL).
  • Assessment: The study will assess the correlation between the magnitude of oscillatory coupling in Measurement 1 with the absolute flow dynamics in Measurement 2 during the designated validation windows.
From date of enrollment until end of both study visits; assessed up to 4 weeks from enrollment.
Correlation between GLYMPHOMETER-derived neurofluid metrics and plasma brain-derived biomarkers.
Tijdsspanne: From date of enrollment until end of both study visits; assessed up to 4 weeks from enrollment.

This outcome evaluates the relationship between neurofluid dynamics and blood-based markers of brain clearance. The statistical method will be a correlation analysis (Pearson or Spearman).

  • Measurement 1 (Variable A): Neurofluid coupling oscillations measured via the GLYMPHOMETER medical™ device (measured as relative changes in HbO, HbR, HbT, and CSF/H2O proportional signal including interhemispheric correlation coefficient across these neurofluidic compartments while gating each of them to very low frequency, respiratory and cardiac frequency bands).
  • Measurement 2 (Variable B): Plasma concentrations of brain-derived proteins/peptides (Aβ40, Aβ42, total/phosphorylated tau, NF-L, GFAP) measured via ultra-sensitive Simoa immunoassay (measured in pg/mL).
  • Assessment: The study will assess the correlation between acute GLYMPHOMETER-derived neurofluid changes and plasma biomarker concentrations before and after intervention.
From date of enrollment until end of both study visits; assessed up to 4 weeks from enrollment.
Qualitative assessment of meditation and breathing experiences.
Tijdsspanne: At each study visit after the meditation practice is completed. Expected acquisition window: 30 minutes; Total number of visits: 2

Qualitative characterization of participant experiences using one-on-one micro-phenomenological interviews.

At each study visit after the meditation practice is completed. Expected acquisition window: 30 minutes; Total number of visits: 2

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Geschat)

16 november 2026

Primaire voltooiing (Geschat)

30 november 2027

Studie voltooiing (Geschat)

30 april 2028

Studieregistratiedata

Eerst ingediend

15 september 2026

Eerst ingediend dat voldeed aan de QC-criteria

23 oktober 2026

Eerst geplaatst (Werkelijk)

29 oktober 2026

Updates van studierecords

Laatste update geplaatst (Werkelijk)

10 november 2026

Laatste update ingediend die voldeed aan QC-criteria

5 november 2026

Laatst geverifieerd

1 september 2026

Meer informatie

Termen gerelateerd aan deze studie

Andere studie-ID-nummers

  • 2026P000655
  • GRT69415 (Ander subsidie-/financieringsnummer: Inner Science Research Foundation)

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

ONBESLIST

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Nee

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren